Renal Cancer

Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy - Beyond the Abstract

Cancer-associated thrombosis is a condition where patients with active cancer have a higher risk of deep vein thrombosis and pulmonary embolism compared to the general population.1-2 Compared to patients without cancer-associated thrombosis, patients with cancer-associated thrombosis have a higher morbidity and mortality, higher likelihood of cancer progression, and increased health care costs.2-4 Specifically, patients with renal cell carcinoma have a higher risk of thromboembolism compared to other cancers, due to a higher risk of thromboembolism, both anatomically through direct invasion of the IVC, as well as biologically through overexpression of tissue factor on cancer cells and cancer cell microparticles.1,5

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

Approval Based on Results From CLEAR/KEYNOTE-581 Trial Demonstrating KEYTRUDA Plus LENVIMA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib


San Francisco, CA (UroToday.com) -- Merck, known as MSD outside the United States and Canada, and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA (KISPLYX® in the European Union [EU] for the treatment of advanced renal cell carcinoma [RCC]), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the first-line treatment of adult patients with advanced RCC.

A renal cell carcinoma tumorgraft platform to advance precision medicine.

Renal cell carcinoma (RCC) encompasses a heterogenous group of tumors, but representative preclinical models are lacking. We previously showed that patient-derived tumorgraft (TG) models recapitulate the biology and treatment responsiveness.

Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma.

Renal cell carcinoma (RCC) is known for its variable clinical behavior and outcome, including heterogeneity in developing relapse or metastasis. Recent data highlighted the potential of somatic mutations as promising biomarkers for risk stratification in RCC.

Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.

Cabozantinib monotherapy is approved in the UK for patients with treatment-naïve intermediate- or poor-risk advanced renal cell carcinoma (aRCC), or patients who received prior vascular endothelial growth factor-targeted therapy.

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α).

Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma.

Acquired therapeutic resistance and metastasis/recurrence remain significant challenge in advance renal cell carcinoma (RCC), thus the establishment of patient-derived cancer models may provide a clue to assess the problem.

Active Surveillance of Renal Masses: The Role of Radiology.

Active surveillance of renal masses, which includes serial imaging with the possibility of delayed treatment, has emerged as a viable alternative to immediate therapeutic intervention in selected patients.

Disparities in the Treatment and Survival of Metastatic Renal Cell Carcinoma.

To evaluate racial, gender, and socioeconomic differences in the treatment of metastatic renal cell carcinoma (mRCC) and their impact on survival.

Patients aged ≥18 years diagnosed with mRCC in the National Cancer Database (2004-2015) were analyzed.

Impact of comorbidity on renal cell carcinoma prognosis: a nationwide cohort study.

Presence of comorbid diseases at time of cancer diagnosis may affect prognosis. We evaluated the impact of comorbidity on survival of patients diagnosed with renal cell carcinoma (RCC), overall and among younger (<70 years) and older (≥70 years) patients.

email news signup